ovarian neoplasms/driska

Povezava se shrani v odložišče

Izberite vrsto razvrščanja

Stran 1 iz 243 rezultatov

Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancer.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

Angiogenesis is a proven clinical target for the treatment of advanced epithelial ovarian cancer. Vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) offer patients potential new treatment regimens as they can be given as monotherapy, in combination with

[A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research Groups of CPT-11 in Gynecologic Cancers].

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

A late phase II study of CPT-11, a new derivative of camptothecin, in uterine cervical cancer and ovarian cancer was carried out by a cooperative study group at 26 institutions. Out of 144 patients enrolled, total cases were 110, involving 55 uterine cervical cancers and 55 ovarian cancers. In

Effect of low-dose oral etoposide on serum CA-125 in patients with advanced epithelial ovarian cancer.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

The effect of oral etoposide on CA-125 serum levels was evaluated in 17 patients with epithelial ovarian cancer and progressive disease during, or relapsing after, prior chemotherapy. Only three patients had measurable lesions at extraperitoneal sites. Five had no measurable lesions. The oral

Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum- and taxane-resistant epithelial ovarian cancer.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

OBJECTIVE To evaluate the efficacy and toxicity of combination chemotherapy with intravenous irinotecan and oral etoposide in women with platinum- and taxane-resistant epithelial ovarian cancer. METHODS Between October 2002 and September 2005, we studied 27 women with platinum- and taxane-resistant

Phase II clinical study of the combination chemotherapy regimen of irinotecan plus oral etoposide for the treatment of recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 101 Group Study).

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

OBJECTIVE To evaluate the efficacy and safety of the combination chemotherapy regimen of irinotecan plus oral etoposide for the treatment of patients with recurrent ovarian cancer after previous treatment with platinum and taxane agents. METHODS A total of 42 patients with recurrent ovarian cancer

Maintenance Therapy in Ovarian Cancer with Targeted Agents Improves PFS and OS: A Systematic Review and Meta-Analysis.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

BACKGROUND Maintenance therapy with targeted agents for prolonging remission for ovarian cancer patients remains controversial. As a result, a meta-analysis was conducted to assess the effectiveness and safety of using maintenance therapy with targeted agents for the treatment of ovarian

[Economic assessment of Caelyx versus topotecan in advanced ovarian cancer].

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

Ovarian cancer is the most frequent cause of death due to gynecologic malignancy in both the United States and in Europe. A phase III investigation compared second line treatment Caelyx with topotecan in patients with advanced epithelial ovarian carcinoma who failed a first-line platinum-containing

High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

OBJECTIVE The goal of this study was to determine the optimal dose of topotecan when used in combination with high-dose melphalan and cyclophosphamide (TMC), and to assess the toxicity and efficacy of the regimen in patients with advanced ovarian cancer. METHODS Fifty-three patients with persistent

Pazopanib and Oral Cyclophosphamide in Women With Platinum-Resistant or -Refractory Epithelial Ovarian Cancer.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

Women with recurrent, multiply-treated epithelial ovarian cancer (EOC) have unfavorable prognosis with limited treatment options after failure of platinum-based regimens. We report here a retrospective analysis of women with recurrent, platinum-resistant EOC treated with an oral

Quality of life in ovarian cancer patients receiving chemotherapy.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

OBJECTIVE A descriptive study was performed to evaluate the variables which influence the quality of life of women with ovarian cancer undergoing chemotherapy treatment. METHODS The study involved a chart review of 60 women with ovarian cancer and analysis of their compiled EORTC QLQ-C30 Quality of

Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

OBJECTIVE The aim of this study was to determine the maximum tolerated dose and dose-limiting toxicity (DLT) of whole abdomen radiation as a chemosensitizer of weekly docetaxel for women with recurrent epithelial ovarian fallopian tube, or peritoneal cancers. METHODS Women were enrolled on one of

[Experience with xeloda (capecitabine) as a component of chemotherapy for relapsing cisplatin-resistant ovarian tumors].

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

The effectiveness and tolerability of xeloda (capecitabine), a tumor-reactivated oral fluoropyrimidine, alone were investigated in 19 patients, aged 39-79, with relapsing and cisplatin-resistant ovarian tumors. Unfavorable prognosis of chemotherapy was in 11 cases (57.8%): cisplatin-resistant tumors

A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

OBJECTIVE To determine the activity of capecitabine in women with platinum-resistant ovarian cancer. METHODS In this multi-centre phase II trial, 35 patients with platinum-resistant ovarian, primary peritoneal or fallopian tube carcinomas were treated with capecitabine 1250 mg/m(2) twice daily for

Attitudes to chemotherapy in patients with ovarian cancer.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

BACKGROUND Recurrent ovarian cancer (OVCA) has become the model for cancer as a chronic disease, yet little is known about what motivates patients and physicians in treatment choices. METHODS We investigated the attitudes of patients with epithelial OVCA and staff towards palliative chemotherapy for

Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

OBJECTIVE Ovarian cancers (OCs) frequently have HER2 activation in the absence of HER2 overexpression. Pertuzumab, a humanized antibody that prevents HER2 dimerization and inhibits multiple HER-mediated pathways, was studied in a phase II, multicenter trial in advanced, refractory

Prejšnji
1
2
3
4
5
6
...
16
17
Naslednji

Pridružite se naši
facebook strani

Herbal & Natural Medicine

Najbolj popolna baza zdravilnih zelišč, podprta z znanostjo

Deluje v 55 jezikih
Zeliščna zdravila, podprta z znanostjo
Prepoznavanje zelišč po sliki
Interaktivni GPS zemljevid - označite zelišča na lokaciji (kmalu)
Preberite znanstvene publikacije, povezane z vašim iskanjem
Iščite zdravilna zelišča po njihovih učinkih
Organizirajte svoje interese in bodite na tekočem z raziskavami novic, kliničnimi preskušanji in patenti

Vnesite simptom ali bolezen in preberite o zeliščih, ki bi lahko pomagala, vnesite zelišče in si oglejte bolezni in simptome, proti katerim se uporablja.
* Vse informacije temeljijo na objavljenih znanstvenih raziskavah